Bhalchandra Kawdikar: FDA Approves Rusfertide for Polycythemia Vera
Bhalchandra Kawdikar, Vice President International Marketing at Edge Pharma (merchant Exporter), shared a post on LinkedIn:
”FDA Approves MIMRYLO Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera Aug 28, 2026.
Why it matters: New hope in reducing the risk of life-threatening conditions due to chronic blood cancer.
PV is a chronic blood cancer. In PV RBC’s are overproduced, increasing the blood viscosity.
This can result in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism.
Takeda’s Mimrylo (Rusfertide) is a first-in-class SC Inj. It mimics the action of hepcidin, (a natural hormone that regulates iron homeostasis and erythrocytosis).
By targeting the underlying mechanism of iron dysregulation MIMRYLO aims reduces excess RBC production and helps maintain hematocrit control.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
-
Sep 3, 2026, 20:29Sarah Robins: Happy to Share This Portrait Film I Voiced for the NNHHF
-
Sep 3, 2026, 20:27Mireille Muller: Europe Needs More Plasma Donors
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:40Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB